Cargando…
埃克替尼在晚期非小细胞肺癌EGFR状态明确的患者中的疗效分析
BACKGROUND AND OBJECTIVE: As the first epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in China, icotinib shows promising anticancer activity in vitro and vivo. The phase Ⅲ clinical study (ICOGEN) showed that icotinib has a good efficacy and tolerability in Chinese patients wit...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6015128/ https://www.ncbi.nlm.nih.gov/pubmed/23514942 http://dx.doi.org/10.3779/j.issn.1009-3419.2013.03.04 |